---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-22-000875"
form_type: "8-K"
ticker: "VANI"
cik: "0001266806"
company_name: "Vivani Medical, Inc."
filed_at: "2022-06-16T23:59:59+00:00"
generated_at: "2026-06-25T01:08:38.210766+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# VP Clinical and Scientific Affairs Jessy Dorn resigns effective July 15, 2022

## Summary
- Dr. Jessy Dorn, VP Clinical and Scientific Affairs, resigned effective July 15, 2022.
- She served Second Sight Medical Products since 2006.
- No replacement has been announced as of the filing date.

## SEC filing metadata
- accession: 0001753926-22-000875
- form_type: 8-K
- ticker: VANI
- cik: 0001266806
- company_name: Vivani Medical, Inc.
- filed_at: 2022-06-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1266806/000175392622000875/0001753926-22-000875-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1266806/000175392622000875/g083057_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-22-000875
- JSON: https://secwatch.observer/filing/0001753926-22-000875.json
- Plain text: https://secwatch.observer/filing/0001753926-22-000875.txt

## Key facts
- Executive change
  Jessy Dorn resigned as Vice President, Clinical and Scientific Affairs at Vivani Medical, Inc..
  - Action: resigned
  - Role: Vice President, Clinical and Scientific Affairs
  source text: On June 13, 2022, Second Sight Medical Products, Inc. received notice from Dr. Jessy Dorn, its Vice President, Clinical and Scientific Affairs, that she will resign from her current position effective July 15, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1266806/000175392622000875/0001753926-22-000875-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.